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Background: A challenge in gene expression studies is the reliable identification of differentially expressed genes.
In many high-throughput studies, genes are accepted as differentially expressed only if they satisfy simultaneously a
p value criterion and a fold change criterion. A statistical method, TREAT, has been developed for microarray data
to assess formally if fold changes are significantly higher than a predefined threshold. We have recently applied the
NanoString digital platform to study expression of mouse odorant receptor genes, which form with 1,200 members
the largest gene family in the mouse genome. Our objectives are, on these data, to decrease false discoveries when
formally assessing the genes relative to a fold change threshold, and to provide a guided selection in the choice of
this threshold.
Results: Statistical tests have been developed for microarray data to identify genes that are differentially expressed
relative to a fold change threshold. Here we report that another approach, which we refer to as tTREAT, is more
appropriate for our NanoString data, where false discoveries lead to costly and time-consuming follow-up experiments.
Methods that we refer to as tTREAT2 and the running fold change model improve the performance of the statistical
tests by protecting or selecting the fold change threshold more objectively. We show the benefits on simulated
and real data.
Conclusions: Gene-wise statistical analyses of gene expression data, for which the significance relative to a fold
change threshold is important, give reproducible and reliable results on NanoString data of mouse odorant
receptor genes. Because it can be difficult to set in advance a fold change threshold that is meaningful for the
available data, we developed methods that enable a better choice (thus reducing false discoveries and/or missed
genes) or avoid this choice altogether. This set of tools may be useful for the analysis of other types of gene
expression data.
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Multiplex gene expression studies that are based on
microarrays and next-generation sequencing result
in the generation of large datasets. The simulta-
neous analysis of the expression of thousands of
genes in these high-throughput approaches challenges
statistical methods and data interpretation. Traditional
statistical tests and analysis tools are therefore often
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reproduction in any medium, provided the orOne of the most popular types of biological experi-
ments is a two-sample comparison. Gene expression
studies often seek to identify genes that are Differentially
Expressed (DE) between RNA samples from two types
of biological conditions, such as gene knockout mice
compared to wild-type mice. DE genes can give insights
into biological mechanisms or pathways, and form the
basis for further experiments. The traditional statistical
method for identifying DE genes between two samples is
the student’s t-test. But a microarray comparative experi-
ment is faced with simultaneously assessing a large num-
ber of genes based on a small number of biological or
technical replicates. Assessing such a large dataset withd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing with many genes but few replicates may lead to large
Fold Changes (FC) driven by outliers, and to small error
variances [1,2]. In order to overcome such problems, the
t-test has been modified for microarray data analysis.
The general idea behind these modifications is to obtain
more stable estimates of the error variance of a given
gene by “borrowing” information from all available genes.
This goal is often obtained by applying (empirical)
Bayesian methods. Examples of these modified tests for
microarray data are the SAM test [3], the regularized
t-test [3,4], and the B-statistic [1,5], as reviewed [2,6,7].
Other statistical approaches for microarray data ana-
lysis have introduced linear models [2,8-10]. These models
allow for more flexibility, for instance when comparing
more than two samples or introducing additional sources
of variation. Such an example is Lin et al. [11], where a
complex experimental design and research goal are ad-
dressed by setting various contrasts in the design of the
linear model. The bioconductor package limma, devel-
oped by Smyth [12], applies a gene-wise linear model, and
allows for the analysis of complex experiments (compar-
ing many RNA samples), as well as more simple replicated
experiments with two RNA samples. The package has fur-
ther developed the ideas of Lönsstedt and Speed [1],
which have been reset within the framework of linear
models in order to address the challenges of microarray
data analysis. The statistic (applied in limma) to identify
DE genes is referred to as the moderated t-statistic,
denoted by t* [5,12]. In the calculation of t*, shrinkage of
the estimated error variances towards a pooled estimate is
obtained through an empirical Bayes approach.
For certain biological problems, it is important to rank
genes according to their FC or to impose on a gene to
attain a predefined FC threshold before calling it DE. In
such situations there remains often a disconnect be-
tween the concepts of a statistically significant differen-
tial expression (based on the p value) and a biologically
meaningful differential expression (FC higher than a
predefined threshold value). Even the modified tests
may result in genes with small FCs to be considered
statistically significant.
In order to integrate these statistical and biological
concepts, a gene can be defined as DE when it satisfies a
p value and a FC criterion [9,13-15]. The advantage of
this combined approach is that the t-test or any of the
modified tests can be combined with an ad-hoc FC cri-
terion. The disadvantage of an ad-hoc FC criterion is
that it does not take into account error variance and
therefore offers no statistical confidence about future
results. In addition, depending on the choice of the FC
criterion and significance criterion, various interpreta-
tions of the same dataset are possible [16]. The moder-
ated t-statistic [5] has been extended by McCarthy andSmyth into a new “test relative to a FC threshold”,
abbreviated TREAT [17]. This method assesses formally
whether the true differential expression is greater than a
predefined FC criterion. TREAT offers greater specificity
and reproducibility in identifying DE genes, compared to
the combined approach of statistical test and ad-hoc FC cri-
terion. TREAT has been also added to the limma package.
We have previously applied the NanoString digital
platform [18] to study the expression of odorant recep-
tor (OR) genes in mice [19,20]. In contrast to microarray
data, where analog levels of fluorescent intensity are
measured, NanoString data represent digital readouts of
single molecules in the form of probe counts. These
probes contain unique fluorescent bar codes, and RNA
abundance of up to 800 genes can be analyzed in a
single reaction in a single tube. The NanoString technol-
ogy thus places itself between qPCR and microarrays in
terms of throughput level [21]. We have analyzed with
NanoString the expression of half of the OR gene reper-
toire of ~1200 genes [19]. Here, we have explored statis-
tical tools for our NanoString data, and developed a
systematic approach for identifying DE genes with re-
spect to a given FC threshold.
We explored the moderated t-statistic (t*), the deriv-
ation of which was driven by microarray data (high
throughput), versus the classical t-statistic on compara-
tive NanoString experiments (medium throughput). We
found that t* does not show a protective effect (i.e. fewer
false discoveries) over t on our NanoString data. But we
also wanted to test whether differential expression is
greater than a FC threshold. Therefore we used the ana-
lysis relative to a FC threshold together with the classical
t-statistic in two approaches. The first approach is similar
to TREAT as published for t* [17], and we refer to it as
tTREAT. Then we addressed the arbitrary choice of the
FC criterion itself, and developed a two-stage approach,
tTREAT2. We describe the performance of TREAT,
tTREAT, and tTREAT2 on our NanoString data, both
in data simulation experiments and on biological data.
The variability of the FC of a gene is inversely related
to the expression level of that gene; lowly expressed
genes tend to have a greater error in their measured FC
levels [4,22]. These lowly expressed genes can thus more
easily reach a certain FC threshold, and the inverse is
true for highly expressed genes. A non-linear model, the
Limit Fold Change model (LFC), has been developed to
identify DE genes based on this relation [22]. We have
applied a similar LFC model on our NanoString data.
We did not use the LFC model as a tool for identifying
DE genes but to set appropriate FC thresholds for genes
with various ranges of expression levels, in order to
avoid a subjective choice of FC criterion. The FC
thresholds that we thus derived were then used in a
subsequent analysis relative to a threshold in order to
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running FC model, and illustrate its use and benefit on
biological data.
Results
Biological data of odorant receptor gene expression
The main olfactory epithelium is located in the nasal
cavity of the mouse, and detects volatile chemicals
(odorants) in the inhaled air. The sense of smell must
detect chemical stimuli with an immense variety in
physicochemical properties. To accommodate this broad
recognition, the mammalian olfactory system has evolved
a large repertoire of molecular receptors, odorant receptors.
These receptors are expressed by olfactory sensory neurons
in the main olfactory epithelium. In the mouse, ~1200
odorant receptors are encoded by distinct genes, which
form the largest gene family in its genome. It is widely
accepted that a mature olfactory sensory neuron ex-
presses only one of the ~1200 odorant receptor genes.
The molecular and genetic mechanisms that regulate this
one receptor - one neuron rule remain unclear, and are
the focus of our research. We have demonstrated the role
of the H element [23] and the P element [24] in the regu-
lation of expression of clusters of odorant receptor genes
by genetically engineering mouse strains that lack the H
element [25] or the P element [19]: these are the ΔH and
ΔP strains and the ΔHxΔP double knockout strain [19].
Another mouse strain is the ΔOlfr7Δ strain [19]; by means
of chromosome engineering [26], we excised a 2.4 mega-
base region on Chromosome 9 that contains the Olfr7
cluster consisting of 99 OR genes [27]. We have also char-
acterized temporal expression patterns of 531 odorant
receptor genes in adult and aged mice [20].
Here we used datasets [19] from a NanoString analysis
of 558 OR genes comparing knockout versus wild-type
mouse strains. Specifically, we used NanoString data
obtained from six mutant mice of the ΔHxΔP strain
(cartridge MK29) compared to 12 control (wild-type)
mice (cartridges MK29 and MK37, six mice each); these
18 mice are in a mixed genetic background, C57BL/6 J ×
129/SvEv. Another dataset was obtained from six mice
of the ΔOlfr7Δ strain, compared to six control (wild-type)
mice (cartridge MK38); these 12 mice are in pure genetic
background, 129/SvEv. With NanoString CodeSet Gorilla,
we determined the RNA abundance for 558 OR genes
from 1 μg RNA of whole olfactory mucosa tissue sam-
ples. Each lane of a NanoString cartridge represents a
different RNA sample and mouse. Thus, there are 6–12
biological replicates per biological condition, and no
technical replicates.
Approaches relative to a FC threshold
Our novel method tTREAT is similar to TREAT [17]. It
is applied to the regular student’s t-statistic, and requiresa predefined FC threshold τ. For the two-stage design,
tTREAT2, a second threshold θ, with θ>τ, is used in a
first “stop and go” stage in which it is decided whether a
gene is non-DE (stop) or whether it can proceed to the
next stage (go). Then, for all the “go” genes, a tTREAT
test with FC threshold τ is applied. In the running FC
model, a non-linear model for FC versus average gene
expression is first used to determine various FC thresh-
olds τi for a number of ranges of expression levels.
Genes are then binned in k gene expression levels, and
the appropriate τi is used per concentration bin in a
subsequent analysis relative to a FC threshold.
Simulated data
Because NanoString data are not yet as widely studied as
microarray data, we have conducted a data simulation
procedure that represents one of our typical two-group
comparison NanoString experiments.
The procedure for simulating one NanoString dataset
was conducted according to the following steps and
distributional assumptions:
 To get a general idea about the variances of
NanoString gene expression data, the genes in the
ΔHxΔP dataset were used as an example gene
population. Biological data from ΔHxΔP mice
were chosen, as they represent a noisier dataset
due to the mixed genetic background of this strain
[19]: the resulting simulated data will not
represent the cleanest example. The ΔHxΔP
dataset was used only for the next step of the
simulation exercise.
 Subsequently, 100 real variances across genes, σ2g ,
were drawn from an inverse-gamma distribution:
Inv −Gamma(g1, g2). The parameters g1 and g2 are
estimated by a Maximum Likelihood procedure in
the above described gene population.
 Each of the 100 σ2g gave rise to three randomly
drawn real differences βg. The σ2g and three
corresponding βg were included in one of the
following three gene groups:
(Group 1) DE genes: The βg were drawn from a
Gaussian eN 0; σgvstart  and had to
satisfy the criterion: |βg| ≥ log2(ω).
(Group 2) Non-DE genes, noisy: Similarly, βg
drawn from eN 0; σgvstart  but with
|βg| < log2(ω).
(Group 3) Non-DE genes, regular: Obviously for
this group the real βg were set to 0.
Note that empirically, the normal distribution
seems acceptable for the βg, based on our
NanoString data.
 The βg that were produced in the previous step
served as true differences that were then
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estimates β^g from a Gaussian eN βg ; σg ﬃﬃﬃﬃzgp .
Similarly residual variances were drawn from a
Chi-square distribution: e σ2gdf g χ2 df g
 
Since the quantity ω used to initiate the simulation as
described above defines the DE genes by the rule |βg| ≥
log2(ω), the distributional center of the β^g of DE genes
actually lies a little further than the actual value of ω,





forth, we will refer to ω as the FC ω with respect to
which the data was simulated.
Every such simulated dataset was thus initially based
on 100 σ2g leading to a total of 900 genes. The regular
non-DE genes (group 3) were fixed as 20% of the 900
genes. However, to assess whether the number of DE
genes in a dataset influences the results, the percentage
of DE genes (and thus also the percentage of the noisy
non-DE genes) was varied between 1% and 40% (noisy
non-DE genes: 79% and 40%, respectively).
On the simulated data, the following statistical ap-
proaches for identifying genes that are DE with regard to
a certain FC threshold were assessed:
(1) TREAT with regard to FC threshold τ
(2) tTREAT with regard to FC threshold τ
(3) tTREAT2 with a bilateral p value calculation in the
second stage with regard to FC thresholds θ
(stage 1) and τ (stage 2)
As the two-stage design tTREAT2 relies on the choice
of two related FC thresholds, one for each of the two
stages, it is not straightforward to compare the perform-
ance of tTREAT2 to TREAT and/or tTREAT. Therefore
we have derived various experimental schemes to show
in which situations the use of a two-stage design like
tTREAT2 can be beneficial.
Results on simulated data
We simulated 400 realizations of a two-group compari-
son NanoString experiment with 900 genes for which
the DE genes are simulated with respect to a certain FC
difference ω as described above. As such we know
beforehand to which group (DE or non-DE) each gene
in these 400 datasets belongs. We can therefore assess
the performance of the procedures described in the
methods section. For this purpose, we fix vstart = 8 and
the significance (type I error) was set at 0.05 or at 0.01.
The mean of the false discoveries (false positives) and
missed genes (false negatives) over the 400 generated
datasets is plotted for the various statistical approaches
for FCs ω (the FC difference with respect to which the
data are simulated) and τ (the actual FC threshold usedin the testing procedure). We also report mean Area
Under the ROC-curve (AUC) values over the 400 gener-
ated data sets.
Figure 1 and Additional file 1 compare TREAT and
tTREAT on a simulation exercise where the FC differ-
ence ω and the FC threshold τ were chosen to be equal.
We tested values for ω = τ of 1.3 (Figure 1A1 and 1A2),
1.5 (Figure 1B1 and 1B2) and 2 (Figure 1C1 and 1C2).
Across the various percentages of DE genes (indicated
on the x axis), the percentages next to the gray and black
bars of tTREAT in Figure 1 represent the percentual de-
crease (prefixed with a minus sign) or increase (prefixed
with a plus sign) in false discoveries or missed genes
with respect to the reference, TREAT. We find that
tTREAT always results in fewer false discoveries than
TREAT, at p = 0.05 and p = 0.01. Moreover, when p = 0.05
is applied as a significance cut-off (Figure 1A1, 1B1 and
1C1), tTREAT decreases the false discoveries for only a
few more missed genes compared to TREAT (Additional
file 2). For p = 0.01 (Figure 1A2, 1B2 and 1C2) the latter is
true for datasets with small percentages of DE genes but
for datasets with ~10% of DE genes, the decrease in false
discoveries is nullified by the increase in missed genes
(Additional file 2). In terms of AUC performance there is
no difference between TREAT and tTREAT across the
percentages of DE genes (Table 1).
In order to illustrate the added value of the safety
margin around the FC threshold τ that has been chosen
for statistical analysis, two simulation experiments were
done. In the first experiment, the data were simulated
such that the actual DE genes had a FC difference ω of
at least 1.5 (up or down), and p was set at 0.01. A blind,
stringent tTREAT test at the higher FC threshold τ of
2.5 (Figure 2A) will result in a high number of missed
genes (dark blue bars, Figure 2B). The reference test for
this scenario is a tTREAT with FC threshold τ = ω = 1.5,
represented by the black and gray stacked bars in Figure 2B.
(See Additional file 3A for stacked bars across 40 per-
centages of DE genes). The stringent tTREAT (τ of 2.5)
decreases, as expected, the false discoveries, by 90% in
comparison to the reference test (cyan vs gray bars,
Figure 2B) but at the cost of a 50% increase in missed
genes (dark blue vs black bars, Figure 2B). When a
two-stage approach is used with FCs θ and τ chosen at
2.5 and 1.5, the high number of missed genes of the
blind, stringent tTREAT test (with FC threshold τ of
2.5) is reduced (red vs dark blue bars, Figure 2B). At
the same time, the two-stage approach has a protective
effect over the reference tTREAT test (FC τ = 1.5) by
decreasing the number of false positives (orange vs grey
bars, Figure 2B). The stringent test has a much lower
AUC than the reference test and two-stage approach
(Table 1). The two-stage approach has the best overall
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Figure 1 False discoveries and missed genes for TREAT and tTREAT on simulated data, at p = 0.05 or at p = 0.01. (A1) The positive y axis
shows the average of the false discoveries, and the negative y axis shows the average of the missed genes for TREAT and tTREAT on 400
simulated datasets. The x axis shows the percentage of DE genes (1%, 10% and 20%) that is simulated in each case. The data are simulated with
respect to a FC difference ω of 1.3 (up or down), and the FC threshold τ used for TREAT and tTREAT is also 1.3. The percentages next to the gray
and black bars of tTREAT represent the percentual decrease (prefixed with a minus sign) or increase (prefixed with a plus sign) in false discoveries
or missed genes with respect to the reference, TREAT (depicted in cyan and blue). The significance cut-off was set at p = 0.05. (A2) Same conditions as
in panel A1, except that significance was set at p = 0.01. (B1) Similar to panel A1, but now the data are simulated with respect to a FC difference ω of
1.5, and the FC threshold τ used for TREAT and tTREAT is also 1.5. The significance cut-off was set at p = 0.05. (B2) Same conditions as in panel B1,
except that significance was set at p = 0.01. (C1) Similar to panel A1, but now the data are simulated with respect to a FC difference ω of 2, and the FC
threshold τ used for TREAT and tTREAT is also 2. The significance cut-off was set at p = 0.05. (C2) Same conditions as in panel C1, except that
significance was set at p = 0.01.
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verse situation. Data are simulated with respect to a FC
of ω = 2.5 (up or down), and p = 0.01. One tTREAT test
aims too low with a FC threshold of 1.5 (purple dashed
lines in Figure 3A), leading to many false discoveries.
The reference test for this scenario is a tTREAT with FC
threshold τ = ω = 2.5, represented by the black and gray
stacked bars in Figure 3B. (See Additional file 3B for
stacked bars across 40 different percentages of DE genes).
A two-stage approach decreases the number of false
positives that are obtained by the non-stringent test
with too low a FC threshold (orange vs light blue bars,
Figure 3B) while maintaining the false negatives (red vs
dark blue bars, Figure 3B). The AUC values show that
the overall performance of these three tests is very
similar (Table 1).
Benefit of tTREAT2 for a biological dataset
We analyzed samples of six ΔOlfr7Δ mutant mice in
comparison to six control mice with our NanoString
Gorilla CodeSet containing 558 OR genes. The Olfr7
cluster contains 99 OR genes, and for 40 OR genes we
could design specific probes. Of these 40 genes, 37 were
defined as informative, as the median of the normalized
NanoString counts in the control mice is at least 100.
Because these 37 OR genes are not present in the gen-
ome of the mutant mice, the counts for these OR genes
in mutant mice should be at background levels, and
these genes are a priori DE. The ΔOlfr7Δ strain is thus
the ultimate negative control for probe specificity. Be-
cause the maximum counts for the negative controls
is ~50, we reasoned that even for expressed Olfr7 cluster
genes with low normalized counts (~130), we could
expect a >2-fold change. We thus set the FC threshold τ
at 2 in a first tTREAT analysis, with p = 0.01. The MC
plot in Figure 4A shows the results: of the 37 genes in
the deleted Olfr7 cluster, 36 are detected as having a FC
significantly lower than ½, but one deleted gene, Olfr916,
is missed. We lowered the threshold to τ = 1.3 in a
second tTREAT analysis: a total of 39 genes is now
identified with a FC significantly lower than 1/1.3 or
higher than 1.3 (Figure 4B). But two genes with a FChigher than 1.3 turn out to reside outside the deleted
cluster: Olfr985, which could perhaps make sense given
it resides close to the deleted region, and Olfr447, which
is on chromosome 6 and ought not to be affected. Im-
portantly, when we apply a two-stage approach, tTREAT2
with θ = 2 and τ = 1.3, the 37 genes of the deleted cluster,
and only these genes, are found to be DE (Figure 4C): no
genes are missed, and no genes outside the cluster are
identified as DE. The experimentally rare case of a dele-
tion mutant, in which certain genes are not present,
thus enables us to demonstrate the benefit of tTREAT2.The running FC model
We applied the running FC model on our NanoString
data obtained from six ΔHxΔP mutant mice and 12
control mice. As these mice are from a mixed genetic
background, we used a less-stringent tTREAT with τ = 1.5,
and p = 0.01. The results are shown as an MA plot in
Figure 5A and as an MC plot in Figure 5C. We find that
nine genes from the P cluster and 12 genes from the H
cluster have a FC significantly lower than 1/1.5. But two
additional genes, Olfr362 on Chromosome 2 and Olfr107
on Chromosome 17, are identified as DE by tTREAT with
τ = 1.5. When we apply a running FC model, a FC thresh-
old value τ is not chosen. Instead the model calculates a
different τ for ten gene expression levels. These values are
≥1.5 for the lower expression levels and drop to 1.36 for
the very high expression levels (Figure 5B). After calculat-
ing the τ values, we applied them together with a tTREAT
test in our running FC model. This model identified 23 DE
genes, 22 of which were also identified by tTREAT with
τ = 1.5 (Figure 5D). The lowly expressed gene Olfr107 (on
Chromosome 17) is no longer identified as DE by the
running FC model, but the model identified an additional
OR gene, Olfr695, which is plausible as it resides within
the P cluster.
The advantage of tests relative to a FC threshold over
combined approaches (statistical test outcome + FC cri-
terion) is illustrated in Figure 5A. By combining the
regular t-test and a FC criterion of 1.5, a total of 49
genes are identified as DE. Of these, 20 reside outside
Table 1 Area under the ROC curve (AUC) for various
methods on simulated data
AUC results completing Figure 1
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AUC results completing Figure 3































*Mean AUC over the 400 simulated data sets with 95% prediction intervals.
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thus in reality most likely not DE.
Discussion
Gene expression has been studied extensively for a wide
variety of biological problems. Over the years various
techniques have been developed for and applied to geneexpression analysis. Ordered from low to high throughput,
these techniques include qPCR, NanoString, microarrays,
and RNA sequencing. These techniques come with their
own specifications, advantages and disadvantages [21,28]
but each also with specific challenges for statistical ana-
lysis. Microarrays have thus far been the most widely used
approach to study gene expression, and have therefore led
to numerous analytical tools and statistical tests. Many of
these tools can also be applied to NanoString data or
qPCR data, and some have resulted in practical software
packages for NanoString [29,30].
The moderated t (referred to as t*) based TREAT,
which was developed for microarray data [5,17] works
well on our NanoString data. But we found that
tTREAT with regular t is even more appropriate.
Moreover, we propose an alternative approach that
defines a safety margin around the FC threshold. This
tTREAT2 application in two subsequent stages can be
beneficial when data are expected to be noisy around
a chosen FC threshold. We also developed a tech-
nique for finding FC thresholds that vary with the ex-
pression level of genes, followed by applying these
objectively set thresholds in tTREAT. In principle, this
running FC model can be applied to gene expression data
obtained with any technique.
The goal of this study is not to determine which
test has the highest performance on NanoString data,
although we describe the overall performance (AUC
values) of TREAT, tTREAT and tTREAT2 on simu-
lated data. Statistical tests like TREAT, fine-tuned to
gene expression data, are difficult to outperform. In
certain situations, however, an alternative test may
prove more beneficial for the technology that is used
and the problem that is studied. In our studies of
odorant receptor gene expression, a falsely discovered
gene leads to extensive follow-up experiments such as
in situ hybridization and even generation of a new
mouse strain by gene targeting. Such follow-up exper-
iments are costly, lengthy, and time-consuming. We
thus need to minimize false discoveries. When using
NanoString data, we find that tTREAT protects more
against false discoveries at significance cut-offs of p =
0.05 and p = 0.01. It is perhaps counterintuitive that
tTREAT instead of TREAT is more beneficial for our
dataset, as TREAT and the moderated t statistic are
known for their ability to decrease false discoveries in
microarray experiments.
There are four main messages. First, we demonstrate
with data simulations that tTREAT is more appropriate
for our NanoString data than TREAT. We used bio-
logical data to initiate data simulation experiments, and
find that tTREAT results in fewer false discoveries com-
pared to TREAT when using significance cut-offs of
p = 0.05 or p = 0.01. But when the percentage of DE
AB
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Figure 2 The two-stage design in a stringent test situation. (A) Data simulation experiment: empirical density functions of the DE genes (solid
curve), noisy non-DE genes (dashed curve), and non-DE genes (dotted curve). The vertical olive lines indicate the simulated FC difference ω between test
and control groups. The choice of ω determines the peak of the density function of the DE genes, which lies a little further. The non-DE genes are
distributed around a FC difference of 0. A stringent test relative to a FC threshold τ, as indicated by the purple dashed lines, identifies only the DE genes
to the right or left of these lines. (B) The positive y axis shows the average number of false discoveries, and the negative y axis shows the average
number of missed genes, over 400 generated datasets for three tests relative to a FC threshold. The x axis shows the percentage of DE genes (1%, 10%
and 20%) that is simulated in each case. Significance is set at p = 0.01. The data are simulated with respect to a FC difference ω of 1.5. The reference
tTREAT with a FC threshold τ of 1.5, thus a test with τ = ω, is depicted in gray and black. The stringent test with a FC threshold τ of 2.5 is in cyan and
blue. The decrease (prefixed with a minus sign) or increase (prefixed with a plus sign) in false discoveries or missed genes with respect to the reference
(tTREAT with τ of 1.5) is indicated above or below the respective colored bar. When applying tTREAT2 (orange and red) the false discoveries are decreased
with regard to the reference test, but the missed genes are not as much increased with regard to the reference test as is the case with the stringent test.
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http://www.biomedcentral.com/1471-2105/15/39genes in the simulated data is high, the advantage of
tTREAT over TREAT in terms of false discoveries is
countered by tTREAT missing more DE genes. When
the overall performance of TREAT and tTREAT is com-
pared by AUCs (thus independently of the chosen p
value), there is no difference on our simulated data. TheTREAT Bayesian approach shrinks (or blasts) the indi-
vidual gene sample variances towards a pooled estimate,
which works particularly well when the number of repli-
cates (arrays) is small; often no more than two replicates
are available for microarrays [5]. The NanoString
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Figure 3 The two-stage design in a non-stringent test situation. (A) Data simulation experiment: empirical density functions of the DE genes
(solid curve), noisy non-DE genes (dashed curve), and non-DE genes (dotted curve). The vertical olive lines indicate the simulated FC difference ω
between test and control groups. The choice of ω determines the peak of the density function of the DE genes, which lies a little further to the
right. The non-DE genes are distributed around a FC difference of 0. A non-stringent test relative to a FC threshold τ, as indicated by the purple
dashed lines, identifies all the DE genes to the right or left of these lines, but also many non-DE genes. (B) The positive y axis shows the average
number of false discoveries, and the negative y axis shows the average number of missed genes, over 400 generated datasets for three tests
relative to a FC threshold. The x axis shows the percentage of DE genes (1%, 10% and 20%) that is simulated in each case. Significance is set at
p = 0.01. The DE genes are simulated with respect to a FC difference ω of 2.5. Here, the reference test is tTREAT with a FC threshold τ of 2.5, thus
a test with τ = ω (gray and black). The non-stringent test with a FC threshold τ of 1.5 is in cyan and blue. When using a safety margin in tTREAT2
(orange and red), the number of false discoveries increases much with regard to the reference test (tTREAT with τ = 2.5), as marked by the positive
percentage above the orange bar. This increase is not as large as is the case with the non-stringent test. The negative percentages underneath their
respective bars show the decrease in missed genes.
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http://www.biomedcentral.com/1471-2105/15/39throughput is much lower (558 genes) compared to
a microarray experiment. So some of the gene-wise
variances may be shrunk (or blasted) by too large afactor when applying TREAT on our NanoString
data, as the hierarchical Bayesian model is expecting
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Figure 4 The two-stage design on biological data: ΔOlfr7Δ
mice. (A) MC plot of 558 OR genes. Filled squares represent genes
that are identified as DE by tTREAT with an FC threshold τ of 2,
comparing ΔOlfr7Δ mutant mice to control (wild-type) mice. The black
stippled rectangle encompasses the 37 genes in the Olfr7 cluster
deletion; these genes do not exist in the genome of ΔOlfr7Δ mice, and
are thus obviously DE. The black arrow indicates a gene (Olfr916) in the
Olfr7 cluster deletion that was missed, thus that was identified as
non-DE. Empty circles represent non-DE genes. (B) MC plot of 558
OR genes. Filled squares represent genes that were identified as DE by
tTREAT with a FC threshold τ of 1.3. The black stippled rectangle
encompasses the 37 genes in the Olfr7 cluster deletion. The black
arrows indicate two OR genes that were identified as DE, but reside
outside of the Olfr7 cluster deletion, and therefore could be false
discoveries. Because Olfr985 is close to the genomic deletion, its
expression could be affected. Empty circles represent non-DE
genes. (C) MC plot of 558 OR genes. Filled squares represent genes
that identified as DE by tTREAT2 with FC thresholds θ = 2 and τ = 1.3.
The black stippled rectangle encompasses the 37 genes in the Olfr7
cluster deletion. Empty circles represent non-DE genes. tTREAT2 now
identifies the 37 genes in the deleted cluster as DE, and no other gene:
there are no missed genes, and no false discoveries.
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non-DE genes showing signs of being increased or de-
creased, it is beneficial to use a safety margin around the
chosen FC threshold in an analysis relative to a FC
threshold. A good choice seems to set θ to τ + 0.5 or τ + 1.
Third, the particular choice of a FC threshold can
influence the interpretation of biological data [16].
The running FC model can be applied in order to
avoid the subjective choice of a FC threshold, or
when data vary strongly with expression levels. We
used the same dataset to determine the FC thresholds
for various gene expression levels and to apply
tTREAT, which may seem suboptimal. It would be ideal
to determine FC thresholds on an independent dataset be-
fore using these thresholds in the subsequent analysis of
the actual data. But often obtaining these independent
data may be too expensive or impossible. We believe that
performing the running FC model on the same dataset
gives accurate results despite its data-driven nature in
such circumstances.
Fourth, the choice of analytical tools must be driven
by the research goals, the gene expression technique,
and the hypothesis that is being tested. TREAT,
tTREAT, or tTREAT2 either give a high number of
false discoveries and few missed genes, only a few
false discoveries for a higher number of missed genes,
or an average but similar number of false discoveries
and missed genes. The inevitable trade-off between false
discoveries and missed genes must be evaluated
dependent on the experimental context. In our case -
NanoString studies of odorant receptor gene expression -
we want to minimize the false discoveries, because the













































































































































































A: Geometric mean of control counts
Combined: t test + FC
Figure 5 Running fold change model on biological data: ΔHxΔP mice. (A) MA plot of 558 OR genes. Filled green squares represent genes
that were identified as DE by tTREAT with a FC threshold of 1.5, comparing ΔHxΔP double mutant mice to control (wild-type) mice. Empty circles
represent non-DE genes. The empty pink circles indicate genes that satisfy the combined criteria of a significant p value for a regular t-test (p < 0.01)
and a FC value >1.5 or <1/1.5. The black vertical stippled line indicates the maximum of the negative controls. The red horizontal stippled line is the
mean of the M values. The yellow stippled lines are equal to M values that represent 1.3 fold up or down: ± log2(1.3). (B) MA plot of 558 OR genes.
Filled green squares represent genes that were identified as DE by a running FC model based on tTREAT. Empty circles represent non-DE genes. The
grey vertical stippled lines delineate ranges of gene expression, for which various FC thresholds have been used. Orange numbers indicate the FC
thresholds that are applied in the subsequent tTREAT analysis. (C) MC plot corresponding to the results shown in panel A. M values are arranged
according to the relative gene order along the chromosomes, which are indicated in various colors. The black arrows indicate two OR genes that have
been identified as DE, but reside outside of the H and P clusters; these are most likely false discoveries. (D) MC plot corresponding to the results shown
in panel C. The solid black arrow indicates an OR gene that has been identified as DE, but resides outside of the H and P clusters, and is most likely a
false discovery. The dashed black arrow indicates an OR gene that is identified as DE and resides within the P cluster; this gene is missed in tTREAT.
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http://www.biomedcentral.com/1471-2105/15/39validation and follow-up experiments are laborious and
expensive. But for other projects, the inverse may be desir-
able: the number of missed genes needs to be minimized,
for instance in large-scale screening of molecules against adrug target, where missing a potential blockbuster drug
cannot be afforded.
In the running FC model, the choice of the FC per-
centile in each bin in the development of the LFC model
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the model (in step 3) affect the final results of the run-
ning FC model, thus the DE genes discovered. Depend-
ing on the percentage of DE genes that is expected,
percentile values ranging from P55 (many DE genes are
expected) to P95 (a few DE genes are expected) are
deemed acceptable. Regarding the number of k bins, a
good coverage of the full expression range of the genes
under analysis should be ensured.
Performance results on a single simulated dataset
(instead of 400) would have been subject to chance
(in favor or disfavor of one method). Repeating the sim-
ulations 400 times permits an understanding of the vari-
ability in test performance that may be obtained between
different simulations. The variability of our mean results
is assessed by the 95% prediction intervals around the
mean number of false discoveries (missed genes re-
spectively) on these 400 data simulations. Neither of
the statistical tests shows outliers in performance that
could contradict our conclusions. Our data simulation
procedure requires a “real” data input at the beginning
only to get an idea about the distribution of gene error
variances for NanoString. This input came from our
data as described in the results. We also used an inde-
pendent, published NanoString data set with ~250 mouse
genes (cell-cycle and G2/M related functions) [31] to
initiate the set of data simulation experiments again.
We find that simulations initiated by these data lead to
very similar results (data not shown).
We present approaches for testing the significance of
gene expression relative to a FC threshold, with a focus
on our NanoString data on OR genes. When carrying
out these hundreds of significance tests simultaneously,
the issue of multiple testing can be raised. A significance
analysis for microarrays (SAM) test has been developed
[3] that encompasses both a test statistic for ranking
(a slightly tuned version of student’s t) and a way to
control the False Discovery Rate and thus to adjust for
multiple testing. The advantage of our approaches is that
they provide p values that can be adjusted by a multiple
testing method of choice, ranging from Bonferroni to
Benjamini and Hochberg [32]. There is a wide variety of
adjustment procedures for multiple testing. The choice
of the most appropriate procedure for a given analysis is
not straightforward. Guidelines and criteria to be attrib-
uted to the multiple testing approaches have been
described [2]. In general, the formulation of a composite
null-hypothesis forces TREAT, tTREAT, and tTREAT2
to rely on a more conservative way of p value calculation
[17]. The distribution of the resulting p values is thus
skewed towards the larger values, which has conse-
quences: (1) if a method for adjusting multiple testing
problems relies on the uniformity of the distribution of
the p values, it cannot be used as this criterion is notmet and (2) we feel that when applied to NanoString
data (for which the technical maximum is 800 genes),
these already conservative p values should not be ad-
justed by yet another conservative method.
For the development of TREAT and initially also for t*
[5,17], it was decided to use gene-wise linear models
with arbitrary coefficients and contrasts of interest (mak-
ing them widely applicable) as a contextual and prac-
tical background; see also the limma package [12]. The
tTREAT, tTREAT2, and the running FC model are also
based on gene-wise linear models. Others [8] have used
linear models, or, more precisely, analysis of variance
models (ANOVA) to assess DE genes in microarray ex-
periments. The main difference is that all genes are in-
cluded in a single linear model, presenting the advantage
that the normalization process is combined with the data
analysis and thus pre-normalization of the data is not
necessary. Obviously for such an ANOVA model to be
justified, its underlying model assumptions should be met,
but they can be assessed quite straightforward. For a
smaller NanoString CodeSet Century [19], which consists
of 89 OR genes and 11 reference genes, we developed
ANOVA models that also dealt with assessing the DE
genes relative to a FC threshold. The negative controls
could not be included in these ANOVA models, as their
residuals were making the general residual distribution
heavily tailed and therefore non-Gaussian. Equality of
variances was not met but within an acceptable borderline
range on these genes. The results of these ANOVA models
were not satisfactory, as the genes that were identified
as DE genes (with FCs significantly higher than a certain
predefined threshold) were sometimes very different
from the TREAT, tTREAT and tTREAT2 results, and
less biologically meaningful. ANOVA models including
various genes in the same linear model can be applied
on NanoString data and may be very useful for certain
purposes. On our data, however, the gene-wise linear
models and thus TREAT, tTREAT, or tTREAT2 were
preferred over an approach that models all genes
simultaneously.
Conclusions
Our gene-wise statistical analysis of gene expression data
with significance relative to a FC threshold gives repro-
ducible and reliable results on NanoString data of odor-
ant receptor genes, the largest gene family in the mouse
genome. Because it is difficult to set a biologically mean-
ingful FC threshold in advance, we have developed
methods that provide guidance in determining a stable
FC threshold (in order to minimize false discoveries and/
or missed genes) or in avoiding this choice altogether.
By applying a two-stage approach, a safety margin around
the FC threshold can be set, which is beneficial in cer-
tain situations. Our running FC model identifies FC
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jective model leading to results that are more reprodu-
cible. This model is well suited for the problem of




A NanoString experiment is performed using one or
more NanoString cartridges, each containing 12 lanes.
In each lane one RNA sample is assayed. The cartridge
is scanned and imaged, resulting in digital readings (raw
counts) for every barcode (gene) in every lane [18]. A
macro can then be used to collect raw counts of car-
tridges of interest into an xls file. We imported these
collected xls files into the R environment, version 2.14
[33]. Counts were processed to eliminate systematic ex-
perimental variability, differing amounts of input RNA,
and variability in background, in three steps: first a
normalization with respect to the geometric mean of the
positive control spike counts, then a normalization with
respect to the geometric mean of a group of five refer-
ence genes, and finally a background correction, which
consists of subtracting the mean + 2*SD (standard devi-
ation) of the negative control counts. Count values <1
were fixed to background level. We define a gene as
informative if the median of the normalized NanoString
counts in wild-type control mice is ≥100.
The FC for gene g can be estimated for any two sam-
ples as the ratio of the geometric mean of the normal-
ized counts of first sample xg 1˜
 
over the geometric
mean of the second sample’s counts xg 2˜
 
: FC ¼ xg 2˜
xg 1˜
.
As ratios are naturally heavily skewed, log2(FC) values,
referred to as M values, are represented in most figures
and analyses instead of the FCs. In MA plots, M values
are plotted against the quantity A, log2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ




which represents an average of the NanoString counts
for that gene. In MC plots, M values are plotted accord-
ing to relative gene order on the chromosomes.
Usage of the limma package
A linear model is fitted to the NanoString expression data
(digital counts) for each gene, which is key in the limma
package [5,12]. We use the log2 of digital NanoString
counts as expression data for every lane for the limma ap-
plication. Thus for a set of l lanes (assumed independent),
there is a log2 counts vector yTg ¼ yg1;⋯ ; ygl
 
for every
gene g. For the linear model on any gene g, we write:
E[yg] =Xψg. The experimental design (i.e. which biological
replicates belong to which RNA sample) is captured bythe design matrix X, and ψg represents the unknown vec-
tor of coefficients. What we are interested in, are
certain contrasts, as given by the contrast’s matrix C (for
example CT = (1, − 1) captures a two RNA group com-
parison): βg = C
Tψg. By fitting the linear model, the ψg
will be estimated which then easily leads to the esti-
mates of the βg. Linear model theory also shows that
Cov ψ^ g
h i
¼ σ2Vg , so the variance-covariance of the
contrasts is deduced as follows: Cov β^g
h i
¼ σ2CTVgC ,
for ease of notation let’s put CTVgC =Zg. Therefore, the
student’s t-statistic for the contrasts in question is then typ-
ically written as follows: tg ¼ β^gsg ﬃﬃﬃzgp , where sg represents the
variance estimator of the unknown gene-wise variance.tTREAT
Let τ be the FC threshold as predefined and Mg the
log2(FC) of a gene g. If we take the example of a two
RNA group comparison, Mg ¼ y 2g— − y 1g— , i.e. the differ-
ence in arithmetic means of the log2 NanoString counts
of the two groups. It can easily be seen how this com-
parison now comes down to a contrast when applying a
linear model to gene g.
The idea of an analysis relative to a FC threshold is to
test the following composite hypothesis: H0 : |Mg| ≤ log2
(τ) against H1 : |Mg| > log2(τ). Thus, H0 is an interval of
values for Mg rather than a single value, which is nor-
mally 0. McCarthy and Smyth [17] determined the exact
(and conservative) p value for this H0 on t* (called
TREAT). We reformulate their ideas for t instead of t*
as follows: Let tobs be the observed value of the t-statistic
for a certain gene g, the p value now equals: p = P{|T| ≥
tobs | H0}. As H0 is an interval, we may find an upper
bound of this p value by choosing the element of H0 that
is the most difficult to reject (hence conservative). So,
let M^obs be the observed value of M^g and choose
M0 ¼ min log2 τð Þ; M^obs
		 		  . Then the actual p value is
bounded above by p ≤ P{|T| ≥ tobs | Mg =M0}. Let δ¼ M0sg ﬃﬃﬃzgp ,
then if tobs ≥ 0, p ≤ 2 * [P{T > tobs − δ| Mg =M0}] and if
tobs < 0, p ≤ 2 * [P{T < tobs + δ| Mg =M0}]. In order to dif-
ferentiate our test from t* and TREAT [17], we refer to
it as tTREAT.tTREAT2
In this two-stage design, we reconsider the relative to
a FC threshold idea at the point where the composite
null hypothesis is formulated: H0 : |Mg| ≤ log2(τ) against
H1 : |Mg| > log2(τ). The interval to which H0 applies,
is thus H0 : − log2(τ) <Mg < log2(τ). A larger interval,
called I, is now defined around H0, for example I :
[−log2(θ), log2(θ)] with θ > τ. Then, in a first stage,
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confidence interval (CI) for Mg is defined as usual:









df stands for the residual degrees of freedom. If this
100% × (1 − αstage1) CI for Mg falls strictly within I, it
is decided to call the gene g as non-DE (stop), other-
wise the gene g goes on to the second stage (go). For
all the go genes, the second stage p value calculation
is done exactly as for the tTREAT part above with
regard to the interval defined by H0. This approach
allows for more flexibility, particularly when there is
concern that the chosen tTREAT FC threshold may be
too high. In such a case, θ could be set to a high
value, and a lower value, e.g. θ − 1 or θ − 0.1, could be
chosen for τ. In a second stage, the type I errors of
both stages, αstage1 (defining the CI) and αstage2 (sig-
nificance of tTREAT analysis on go genes), can be
chosen freely and may differ from each other. Here we
have chosen αstage1 to equal 0.05. The value of θ (and
thus the length of the interval I) and its difference
with regard to τ allow for a safety margin around τ,
thus helping to reduce false positives in noisy data
while keeping the false negatives fixed or reducing
them as well.Running FC model
By using a fixed FC threshold, genes with lower expression
levels have a greater chance of being identified as DE
because of their higher variance. In order to determine
which FC threshold is appropriate for a certain expression
level (or range of expression levels), we developed a
running FC model. We used a model similar to [22] to
find a potential FC cut-off function. Then we applied this
function is to a number of ranges r of different expression
levels, resulting in r different FC thresholds to use in any
type of subsequently applied analysis. A step-by-step de-
scription of the running FC model is as follows.
1. Discrete relationship between FC and average gene
expression levels:
Any two-by-two comparison of RNA groups is consid-
ered separately in the model. For simplicity, assume
there are only two RNA groups as above. For the run-




every gene g. When FCg is < 1, the reciprocal is taken.
Then the Mg = log2(FCg) values are plotted against the
average expression levels (ARg) of the reference group
(say group 1, in our case these are the control mice),
ARg ¼ xg 1˜ . Subsequently, the overall AR range is divided
into bins of different widths but containing an equal num-
ber of genes. In each bin j (j= 1,⋯ ,m), the b%-percentile
of the FCg for all genes in that bin is determined and named
bpJ. All these bpJ can be visualized on the M-AR plot.2. Fitting a continuous function:
As in [22], the equation bp = a + b/AR (where AR
stands for the median of the ARg values in a certain bin
j) seems to fit the data quite well. A least-squares fit of
this equation is thus fitted to model the FC b-percentiles
over various gene expression levels.
3. Defining the appropriate FC thresholds for various
gene expression levels:
The model fit of step 2 is used to get actual FC thresh-
old values for a number k of gene expression level
ranges. In this case the bins of gene expression ranges
are typically distributed more evenly over the full AR
range, in contrast to the binning in step 1. For each of
the i different ranges (i = 1,⋯ , k) we apply the FCi, as
defined by the model fit of step 2, to all genes in that
specific range i of expression values as a FC threshold
value for any kind of analysis (TREAT, tTREAT, or
tTREAT2). The complete analysis is then referred to as
the running FC model.
Calculation of the Area Under the ROC curve (AUC)
The R open-source package pROC was used to calculate
AUC values of statistical tests [34].
Software for the tools
A zip file of a folder containing the functions in R code
[33] to use the analytic tools developed here (tTREAT,
tTREAT2, running FC model, and MA and MC plots)
is available as Additional file 4. The folder also contains
an R script as an example of how to apply these func-
tions. The ReadMe file illustrates and explains how to
use the tools.
Availability of supporting data
The biological datasets (MK29, MK37 and MK38) support-
ing the results of this article are available in the NCBI Gene
Expression Omnibus [35], and are accessible through GEO
Series accession number GSE53876: http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE53876.
Additional files
Additional file 1: False discoveries and missed genes for TREAT and
tTREAT on simulated data, at p = 0.01. (A) The positive y axis shows
the average of the false discoveries, and the negative y axis shows the
average of the missed genes for TREAT and tTREAT on 400 simulated
datasets. The x axis shows 40 different percentages of DE genes (ranging
from 1% to 40%) that is simulated in each case. The data are simulated
with respect to a FC difference ω of 1.3 (up or down), and the FC
threshold τ used for TREAT and tTREAT is also 1.3. The black percentages
next to the gray and black bars of tTREAT represent the percentual
decrease (prefixed with a minus sign) or increase (prefixed with a plus
sign) in false discoveries or missed genes with repect to the reference,
TREAT (depicted in cyan and blue). Significance is set at p = 0.01. (B)
Similar to panel A but now the data are simulated with respect to a FC
difference ω of 1.5, and the FC threshold τ used for TREAT and tTREAT is
also 1.5. (C) Similar to panel A but now the data are simulated with
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and tTREAT is also 2.
Additional file 2: Mean false discoveries and missed genes,
together with 95% prediction intervals on simulated data.
Additional file 3: Benefit of using the two-stage design in a
stringent/non-stringent test situation. (A) The positive y axis shows
the average number of false discoveries, and the negative y axis shows
the average number of missed genes, over 400 generated datasets for
three tests relative to a FC threshold. The x axis shows 40 different
percentages of DE genes (ranging from 1% to 40%) that is simulated in
each case. Significance is set at p = 0.01. The DE genes are simulated with
respect to a FC difference ω of 1.5. Here, the reference test is the original
tTREAT with a FC threshold τ of 1.5, thus a test with τ = ω (in gray/black).
The stringent test with a FC threshold τ of 2.5 is in cyan and blue. The
tTREAT2 is in orange and red. (B) The positive y axis shows the average
number of false discoveries, and the negative y axis shows the average
number of missed genes, over 400 generated datasets for three tests rela-
tive to a FC threshold. The x axis shows 40 different percentages of DE
genes (ranging from 1% to 40%) that is simulated in each case.
Significance is set at p = 0.01. The DE genes are simulated with respect to
a FC difference ω of 2.5. Here, the reference test is the original tTREAT
with a FC threshold τ of 2.5, thus a test with τ = ω (in gray and black).
The non-stringent test with a FC threshold τ of 1.5 is in cyan and blue.
The tTREAT2 with FC thresholds 2.5/1.5 is in orange and red.
Additional file 4: Software. A zip file of a folder containing the
functions in R code to use the analytic tools developed here (tTREAT,
tTREAT2, running FC model, and MA and MC plots). The folder also
contains an R script as an example of how to apply these functions. The
ReadMe file illustrates and explains how to use the tools.
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